« Return to News | Drug Sponsors

AgonOx, MedImmune partner to develop cancer therapies

Monday, October 31, 2011 11:57 AM

AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

"We are very pleased to collaborate with MedImmune to advance our OX40 agonist programs," said AgonOx CEO Llew Keltner, M.D., Ph.D. "MedImmune has impressive capabilities in immuno-oncology, and we believe offers great potential for eventually bringing therapies utilizing the OX40 mechanism to trigger tumorspecific immune responses to patients."

MedImmune will also support further OX40 research at Providence Cancer Center, where the foundational preclinical and clinical development of OX40 has been conducted. Additional details of the agreement will not be disclosed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.